Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

NCT04849910 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

67

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Funding

Conditions

Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions

BIOLOGICAL: VOR33
DRUG: Mylotarg

Sponsor

Vor Biopharma